Vertex researchers will conduct two 24-week Phase 3 studies on the affect of VX-809 and ivacaftor in CF patients with two copies of the F508del mutation.

The NHLBI has launched a program that focuses on infants and young children who have cystic fibrosis that could provide a road map for prevention.

The Anti-Infective Drugs Advisory Committee to the US Food and Drug Administration voted today in favor of the use of TIP by cystic fibrosis patients.

Researchers at the University of Iowa Carver College of Medicine have discovered a genetic process that can restore function to a defective protein, the most common cause of cystic fibrosis.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today final data from a Phase 2 study of VX-809 and KALYDECO™ (ivacaftor) that showed statistically significant improvements in lung function among adults with cystic fibrosis (CF) who have two copies (homozygous) of the most common mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, F508del.

Inhaling concentrated saline mist does not reduce how often infants and young children with CF need antibiotics for respiratory symptoms, according to findings from a recent clinical trial.

A major international research effort has led to a new online resource that provides information about specific cystic fibrosis gene mutations to people with CF and their families, researchers, health professionals and the general public.

Scientific American magazine reviews two new research papers - recently published in the journal Science - showing how some bacteria are able to withstand antibiotic treatment.

Genzyme and Cystic Fibrosis Foundation Therapeutics Inc. today announced a research agreement to support the discovery of new drugs to treat people with the most common mutation found in patients with CF, Delta F508.

The National Institutes of Health has awarded Agile Sciences a grant to evaluate the efficacy of anti-biofilm molecules for treating lung infections of cystic fibrosis patients.

A poll by the University of Michigan found that 84 percent of parents say they don't know about opportunities for their children to participate in medical research.

Researchers at the University of Iowa have discovered that in CF patients, the airway glands are depleted of a specific population of airway stem cells that participate in airway repair following injury.

Microbiologists have uncovered a sneaky trick by the bacterium Pseudomonas aeruginosa to oust rivals. Its means of attack helps it survive in the outside environment and may even help it cause infection.

UCLA researchers learn more about how bacteria move across surfaces prior to forming multicellular bacterial biofilms.

A study published in the Journal of the American Medical Association says treatment based on a new invasive diagnostic procedure for treating CF in infants did not have a lower prevalence of lung-damaging infection or structural lung injury at age five.

Researchers at UCLA have identified a new stem cell that participates in the repair of the large airways of the lungs, which play a vital role in protecting the body from infection.

Researchers at Duke University Medical Center have made new discoveries about mouse basal cells that line airways which could help provide new therapies for either blocked or thinned airways.

Scientists may have discovered an entirely new way to change the genetic code. The findings may ultimately help researchers alter the course of devastating genetic disorders, such as cystic fibrosis.

Mutations in genes essential to survival are behind so-called orphan diseases, explaining in part why these diseases are rare and often deadly, according to a study appearing in The American Journal of Human Genetics.

A bacteria which infects people with cystic fibrosis could help combat other antibiotic-resistant microbes, according to a team from Cardiff and Warwick Universities in Great Britain.

Researchers at the Johns Hopkins Institute for Genetic Medicine have discovered two regions of the genome that affect the severity of cystic fibrosis.

A genetic test from Abbott provides information used for cystic fibrosis carrier screening, newborn screening and confirmation of CF diagnoses in newborns and children.

Canadian high school student Marshall Zhang used the Canadian SCINET supercomputing network to find a potentially effective drug cocktail to treat cystic fibrosis.

A Johns Hopkins Children's Center study of kids with CF shows that simple exercise, individually tailored to each patient’s preference and lifestyle, can help improve lung function and overall fitness.

An over-the-counter drug used to treat diarrhea combined with minocycline, an antibiotic used to treat bacterial infections, could one day change the lives of those living with cystic fibrosis.

Researchers from IBM and the Institute of Bioengineering and Nanotechnology discovered a nanomedicine breakthrough in which new types of polymers were shown to physically detect and destroy antibiotic-resistant bacteria and infectious diseases like Methicillin-resistant Staphylococcus aureus, known as MRSA.

A pig model that replicates the most common form of CF can be useful in learning about the CFTR protein's properties, researchers have found.

Researchers soon will explore 4-D imaging of lungs in young children with CF.

Axcan President and CEO Frank Verwiel explains how Axcan's merger with Eurand will affect customers.

An imbalance of salt and water in patients with cystic fibrosis makes their lungs clog up with sticky mucus that is prone to infection. The cause of the offending imbalance is a well-known genetic error, one that blocks the molecular expressway for tiny chloride ions to move across the surface of the lungs. But how does that same gene mutation upset a parallel roadway controlling the flow of the other component of salt, sodium ions?

A new study using a pig model of cystic fibrosis (CF) suggests that low levels of a growth promoting hormone at or before birth may contribute to growth defects in patients with CF.

Note from BEF: This Metabolon press release details a newly published research paper. The paper's findings "reveal novel metabolic abnormalities associated with the CF pathological process and identify a panel of potential biomarkers for therapeutic development using this model system," according to Metabolon. The company's metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization.

A new study links flare-ups of cystic fibrosis to a chronic bacterial infection, a finding that could give physicians new insight into the disease and offer a new target for medication.

Human growth hormone can be used successfully to treat some symptoms of cystic fibrosis, but its impact on the disease itself remains unknown, according to a new report funded by U.S. Department of Health and Human Services' Agency for Healthcare Research and Quality (AHRQ).

A University of Texas at Austin College of Pharmacy researcher has received a $2.1 million grant to develop new techniques for drug delivery to the lungs, helping in the fight against such lung diseases as cystic fibrosis.

Vitamin D may be an effective therapy to treat and even prevent allergy to a common mold that can cause severe complications for patients with cystic fibrosis and asthma, according to researchers from Children's Hospital of Pittsburgh of UPMC, the University of Pittsburgh School of Medicine and Louisiana State University School of Medicine.

Luminex Corp. announced the full commercial launch of a new diagnostic test that can simultaneously screen a single blood sample for up to 60 cystic fibrosis-causing genetic mutations in a matter of hours.

A study published today in the Journal of the American Medical Association examines the effect that methicillin-resistant Staphylococcus aureus (MRSA) has on people with cystic fibrosis. It found that chronic infection with MRSA in people with CF was associated with worse survival than those who don't have the bacteria.

Ten years after President Bill Clinton announced the completion of the first draft of the Human Genome Project, its application to drug development is still, at best, a work in progress. But while many genetics scientists outside the drug industry say the project has had few medical benefits, industry researchers urge a wait-and-see patience.